Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

2.

Prevention of graft-versus-host disease by adoptive T regulatory therapy is associated with active repression of peripheral blood Toll-like receptor 5 mRNA expression.

Sawitzki B, Brunstein C, Meisel C, Schumann J, Vogt K, Appelt C, Curtsinger JM, Verneris MR, Miller JS, Wagner JE, Blazar BR.

Biol Blood Marrow Transplant. 2014 Feb;20(2):173-82. doi: 10.1016/j.bbmt.2013.10.022. Epub 2013 Nov 1.

3.

Inflammatory mediators influence the expression of nociceptin and its receptor in human whole blood cultures.

Zhang L, Stuber F, Stamer UM.

PLoS One. 2013 Sep 16;8(9):e74138. doi: 10.1371/journal.pone.0074138. eCollection 2013.

4.

Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Donica CL, Awwad HO, Thakker DR, Standifer KM.

Mol Pharmacol. 2013 May;83(5):907-18. doi: 10.1124/mol.112.084632. Epub 2013 Feb 8. Review.

5.

NOP Receptor Ligands as Potential Agents for Inflammatory and Autoimmune Diseases.

Gavioli EC, Romão PR.

J Amino Acids. 2011;2011:836569. doi: 10.4061/2011/836569. Epub 2011 Nov 17.

6.

Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Lohith TG, Zoghbi SS, Morse CL, Araneta MF, Barth VN, Goebl NA, Tauscher JT, Pike VW, Innis RB, Fujita M.

J Nucl Med. 2012 Mar;53(3):385-92. doi: 10.2967/jnumed.111.097162. Epub 2012 Feb 6.

7.

Orphanin FQ/nociceptin activates nuclear factor kappa B.

Donica CL, Ramirez VI, Awwad HO, Zaveri NT, Toll L, Standifer KM.

J Neuroimmune Pharmacol. 2011 Dec;6(4):617-25. doi: 10.1007/s11481-011-9279-2. Epub 2011 May 6.

8.

Nociceptin/orphanin FQ suppresses adaptive immune responses in vivo and at picomolar levels in vitro.

Anton B, Leff P, Meissler JJ, Calva JC, Acevedo R, Salazar A, Matus M, Flores A, Martinez M, Adler MW, Gaughan JP, Eisenstein TK.

J Neuroimmune Pharmacol. 2010 Mar;5(1):143-54. doi: 10.1007/s11481-010-9190-2. Epub 2010 Feb 2.

9.

Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions.

Chapman CR, Tuckett RP, Song CW.

J Pain. 2008 Feb;9(2):122-45. Epub 2007 Dec 21. Review.

10.

Rising plasma nociceptin level during development of HCC: a case report.

Horvath A, Folhoffer A, Lakatos PL, Halosz J, Illyes G, Schaff Z, Hantos MB, Tekes K, Szalay F.

World J Gastroenterol. 2004 Jan;10(1):152-4.

11.

Increased nociceptin/orphanin FQ plasma levels in hepatocellular carcinoma.

Szalay F, Hantos MB, Horvath A, Lakatos PL, Folhoffer A, Dunkel K, Hegedus D, Tekes K.

World J Gastroenterol. 2004 Jan;10(1):42-5.

12.

Human neutrophils as a source of nociceptin: a novel link between pain and inflammation.

Fiset ME, Gilbert C, Poubelle PE, Pouliot M.

Biochemistry. 2003 Sep 9;42(35):10498-505.

Supplemental Content

Support Center